Abstract
Objectives:
Recently, after almost 50 years of dormancy, new therapeutic agents for the management of gout have entered the market or are in clinical development. In this article, the current guidelines for the diagnosis and management of gout are reviewed.
Methods:
Key papers for inclusion were identified by a PubMed search, and articles were selected according to their relevance for the topic, according to the authors’ judgment.
Results and conclusions:
Although our therapeutic arsenal is strong, and effective gout management with urate lowering therapy improves many patient-reported outcomes in clinical trials, major gaps exist in patient understanding of disease and adherence to long-term therapy. Research is required to identify the optimal models of care for patients with gout. However, quality of care in gout can be enhanced through better gout-centered education. To properly manage gout, education of the gout patient is critical, since only the patient who understands their gout will stay with their medication long-term.
Transparency
Declaration of funding
Menarini International provided funding for editorial assistance.
Declaration of financial/other relationships
T.B. has disclosed that he has received fees for consulting or presentations from Menarini, Ipsen, Takeda, Savient, Sobi, Novartis, Biocryst, Ardea Biosciences, and Mayoli Splinder. G.D. has disclosed that he/she has no significant relationships with or financial interests in any commercial companies related to this study or article.
CMRO peer reviewers on this manuscript have received honoraria for their review work, but have no other relevant financial relationships to disclose.
Acknowledgments
Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli PhD on behalf of Content Ed Net.